Item 7.01 중요

공정공시

Item 7.01 of this Report (including Exhibit 99.1), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01

기타 이벤트

어큐멘 파마슈티컬스가 알츠하이머병 치료제 sabirnetug의 2상 임상시험 ALTITUDE-AD에서 주요 평가지표 달성에 실패했다고 발표했다. 회사는 sabirnetug 개발 중단 및 현금 보존 조치와 전략적 옵션 검토를 계획하고 있다.